Treatment with LSD1 inhibitors and simultaneous repression of glycolysis may enhance the efficacy of treatment by killing senescent cancer cells but also could increase the range of tumours susceptible to growth inhibition by LSD1 inhibitors. The gene discussed is KDM1A; the disease is neoplasm.